

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.


The rejection of claims 51-55, 60, 63, 66, 84, and 85 under 35 U.S.C. § 102(b) as anticipated by U.S. Patent No. 4,340,600 to Brenner et al. ("Brenner") is respectfully traversed.

Brenner discloses 4-phenyl-1,2,3,4-tetrahydroisoquinolines and their use in renal dilating methods. However, as to the pending claims, Brenner fails to teach the limitation "wherein if R^3 is $-S(O)_nR^{12}$, n cannot be 0, and wherein if R^3 is $-OR^{11}$, R^{11} cannot be hydrogen". In the outstanding office action, it is asserted that Brenner teaches the compounds of Formula IB where R^3 is $-OR^{11}$ and R^{11} is $(CO)R^{13}$ when R^{13} is methyl, as set forth in Example 10 of the present application. However, by the above amendments, Formula IB no longer permits substituent R^3 to be $-OC(O)R^{13}$. In addition, the specific substituents required by the separately claimed classes of compounds IA-F are not taught by Brenner. Since Brenner fails to teach or suggest compounds satisfying these limitations, it cannot anticipate the claimed invention. Accordingly, the rejection under 35 U.S.C. § 102 should be withdrawn.

In view of all of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: July 20, 2005



Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

